{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:48:53Z","timestamp":1774604933492,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Clinical Hypertension"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The goal of the TREAT study is to estimate the prevalence of true resistant hypertension in a Belgian setting of patients with apparent treatment resistant hypertension (aTRH) and to evaluate which determining factor of pseudo\u2010resistant hypertension contributes the most to this prevalence.<\/jats:p>\n                  <jats:p>TREAT is a single\u2010visit, multicentric, non\u2010interventional, cross\u2010sectional survey. Inclusion criteria included: patients over 18 years receiving 3 or more antihypertensive molecules and referred to specialized hospital centers for aTRH.<\/jats:p>\n                  <jats:p>A total of 201 eligible patients were included. Only 56.7% of the patients were treated with the guideline recommended triple combination therapy (i.e. renin\u2013angiotensin\u2013aldosterone system inhibitor, calcium channel blocker and thiazide (\u2010like) diuretic), and only 23.4% were treated with the maximal recommended dose. WCH was present in 8.7% of the 115 patients with available ambulatory blood pressure recordings. Therapeutic adherence was self\u2010reported as good by 80% of patients, while 20% reported poor or moderate adherence. In this cohort, the prevalence (95% CI) of true resistant hypertension was estimated at 21.9% (14.7%\u201330.6%).<\/jats:p>\n                  <jats:p>Among patients referred to specialized centers for aTRH, about 3 out of 4 presented with pseudo\u2010resistant hypertension. The occurrence of WCH and poor adherence appeared rather limited in our study, but half of the participants were polymedicated with non\u2010recommended combinations of antihypertensive molecules. Inadequate dosing was observed in the majority of patients and a third was not using a single pill combination. Hence, pseudo\u2010resistant hypertension seems to be mainly associated with the underuse of triple combination therapy and, most likely, with suboptimal dosing.<\/jats:p>","DOI":"10.1111\/jch.70230","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:34:32Z","timestamp":1773754472000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TREAT: A Multicentre Cross\u2010sectional TReatment Evaluation of Apparent Resistant hyperTension in Belgium"],"prefix":"10.1111","volume":"28","author":[{"given":"Brouwers","family":"Sofie","sequence":"first","affiliation":[{"name":"Cardiovascular Center Aalst AZORG Clinic Aalst Aalst Belgium"},{"name":"Department of Experimental Pharmacology Vrije Universiteit Brussel Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huart","family":"Justine","sequence":"additional","affiliation":[{"name":"Division of Nephrology University of Li\u00e8ge Hospital (ULi\u00e8ge CHU) Li\u00e8ge Belgium"},{"name":"Groupe Interdisciplinaire de G\u00e9noprot\u00e9omique Appliqu\u00e9e (GIGA), Cardiovascular Sciences, University of Li\u00e8ge Li\u00e8ge Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chabot","family":"Mathilde","sequence":"additional","affiliation":[{"name":"Servier Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van Nieuwenhuyse","family":"Bregt","sequence":"additional","affiliation":[{"name":"Servier Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De Bacquer","family":"Dirk","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care Ghent University Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munhoz","family":"Daniel","sequence":"additional","affiliation":[{"name":"Cardiovascular Center Aalst AZORG Clinic Aalst Aalst Belgium"},{"name":"Department of Advanced Biomedical Sciences University Federico II Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"e_1_2_13_2_1","volume-title":"The Race Against a Silent Killer","author":"World Health Global report on hypertension","year":"2023"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01225-8"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.1421"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00590-0"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae178"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5180"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12191"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-021-00631-3"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2013.140"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7117.2000.tb00211.x"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-313599"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.06.017"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-024-01309-0"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.37349\/emed.2025.1001276"}],"container-title":["The Journal of Clinical Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.70230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jch.70230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jch.70230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:49:19Z","timestamp":1774601359000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jch.70230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/jch.70230"],"URL":"https:\/\/doi.org\/10.1111\/jch.70230","archive":["Portico"],"relation":{},"ISSN":["1524-6175","1751-7176"],"issn-type":[{"value":"1524-6175","type":"print"},{"value":"1751-7176","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"2025-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70230"}}